

# WAVERLEY PHARMA – CORPORATE PRESENTATION 2023



# WAVERLEY PHARMA

## Forward-Looking Statements

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements and other estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's potential product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's

products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities.

**SOURCE** Waverley Pharma Inc.



CONFIDENTIAL

---

# WAVERLEY PHARMA

## Waverley Pharma Overview

- A specialty pharma company dedicated to the development and commercialization of safe, effective and affordable therapeutic products
- Currently focused on the development of its PARP-1 inhibitor project
- Partnering with contract manufacturing organizations to develop and commercialize additional oncology products for the US market
- Carefully monitor opportunities and possible acquisitions of related pharmaceutical products in order to realize long term value

---

## WAVERLEY PHARMA - MANAGEMENT

### Larry Thiessen, President & CEO

- 28 years of pharmaceutical experience having worked for Bausch Health Companies Inc. (formerly Biovail Corporation)
- He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation
- Bachelor of Science in Biology and an Executive M.B.A.

### Haaris Uddin, BSc Commerce (Honours), CPA, Chief Financial Officer

- Mr. Uddin joined Waverley Pharma August 2019
- Experience with Ernst & Young as a senior accountant, working with life science companies in both Canada and the United States (Houston, and San Francisco)

# WAVERLEY PHARMA – CURRENT PRODUCTS

## Generic drugs:

### UK Marketed Generic Drugs:

*Capecitabine* – is a chemotherapy drug used to treat breast cancer, gastric cancer and colorectal cancer.

*Temozolomide* – is a chemotherapy drug used for the treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.

*Pemetrexed* – is a chemotherapy drug used to treat pleural mesothelioma non small cell lung cancer

### UK & EU Approved Generic Drugs:

*Bortezomib* – is a chemotherapy drug used to treat multiple myeloma and mantle cell lymphoma

*Pemetrexed* – is a chemotherapy drug used to treat pleural mesothelioma non small cell lung cancer

### US Approved Generic Drugs:

*Bortezomib* – is a chemotherapy drug used to treat multiple myeloma and mantle cell lymphoma

*Pemetrexed* – is a chemotherapy drug used to treat pleural mesothelioma non small cell lung cancer

# WAVERLEY PHARMA – CURRENT PRODUCTS

## In Development:

**Discovery:** *PARP-1 Inhibitor* – small molecule drug - a new class of anticancer agents targeting DNA repair mechanism

- **PARP inhibitors application treatments:**

- leukemia
- pancreatic cancer
- breast cancer
- ovarian cancer, etc.

- **Our project goals :**

- Identify a novel and potent PARP-1 inhibitor drug candidate
- Fine tune PARP-1 selectivity vs PARP-2

- **Our project progress**

- Active compounds at sub-nanomolar concentrations have been identified having superior selectivity compared to already FDA approved PARP-1 inhibitors.
- Provisional Patent submitted

# WAVERLEY PHARMA – MARKET OVERVIEW

## Leading Hospital Oncology Small Molecules

The Top 50 Oncology small molecules represent 90% in value and 63% in volume of total Oncology small molecules, among these 36 molecules are not yet genericized given a great opportunity to develop high value & competitive portfolio for the next decade (markets details in Annexure 1)



LENALIDOMIDE	POMALIDOMIDE	SUNITINIB	TRABECTEDIN	BENDAMUSTINE*
BORTEZOMIB	RUXOLITINIB	EVEROLIMUS	ERIBULIN	EPIRUBICIN*
IBRUTINIB	OXALIPLATIN*	CABAZITAXEL	CRIZOTINIB	AFATINIB
PEMETREXED	DABRAFENIB	OSIMERTINIB	SORAFENIB	VEMURAFENIB
PACLITAXEL*	CARFILZOMIB	TRAMETINIB	CABOZANTINIB	VISMODEGIB
ENZALUTAMIDE	NILOTINIB	TEMOZOLOMIDE*	CAPECITABINE*	VINORELBINE*
ABIRATERONE	DOCETAXEL*	FULVESTRANT**	GEFITINIB	IDELALISIB
AZACITIDINE	DASATINIB	PAZOPANIB	OLAPARIB	ERLOTINIB
IMATINIB*	IRINOTECAN*	GEMCITABINE*	DECITABINE	IXAZOMIB
PALBOCICLIB	DOXORUBICIN*	CARBOPLATIN*	TIPRACIL#TRIFLURIDINE	METHOTREXATE*
<b>TOP 10</b>	<b>TOP 20</b>	<b>TOP 30</b>	<b>TOP 40</b>	<b>TOP 50</b>

\* Molecules already genericized

\*\* Dispensed mainly in Retail (outpatients)

Source: IQVIA-MIDAS

# WAVERLEY PHARMA – UK MARKET

## Status of MHRA Approvals

- MHRA Approvals
  - Capecitabine – 150mg and 500mg
  - Temozolomide – 5mg, 20mg, 100mg, 140mg, 180mg and 250mg
  - Bortezomib – 1mg and 3.5mg
  - Pemetrexed – 100mg and 500mg
- Contracts in process
- Wholesale Distribution Authorization (WDA) License
- Pharmacovigilance Contract and SOPs in place
- First sales October 2018






# WAVERLEY PHARMA – US MARKET

## FDA Approvals

- Pemetrexed 100mg & 500mg
- Bortezomib 3.5mg



Source: Grandview Research

CONFIDENTIAL

## WAVERLEY PHARMA – KEY FINANCIAL INFORMATION

### Capital Structure as of November 29, 2023

- Common shares issued and outstanding: 54,000,000
- Share Price: \$0.035
- Market Cap \$1,890,000